Regenerative 5 min read

BPC-157 — Mechanism, Evidence and Half-Life

A 15-amino-acid fragment derived from a human gastric protein and the most-studied 'body-protective' peptide in animal models. What the published literature actually shows and what it still does not.

BPC-157 — "Body Protection Compound 157" — is a synthetic 15-amino-acid fragment of a sequence first isolated from human gastric juice. Despite the dramatic-sounding name, the compound has a remarkably consistent story in the published animal literature: in models of tissue injury, it appears to accelerate repair. In healthy tissue, it appears to do very little.

That tidy summary hides a lot of nuance, and a good deal of speculation, which is what this guide is here to unpack.

What it is

BPC-157 is a pentadecapeptide — 15 amino acids long, sequence GEPPPGKPADDAGLV. It is not found anywhere in nature in this exact form; it was designed by Sikiric and colleagues at Zagreb in the early 1990s from a fragment of a larger gastric protein. The fragment was chosen for its observed cytoprotective activity in early stomach-ulcer models and synthesised as a stand-alone research compound.

It is stable in gastric acid (unusual for a peptide), and most published work uses subcutaneous, intraperitoneal or oral administration in rats and mice.

Mechanism — what we think we know

There is no single, clean receptor story for BPC-157, and that's a genuine limitation of the field. The most-cited proposed mechanisms are:

Nitric-oxide system modulation. Multiple papers report effects on endothelial NO synthase and on the L-arginine / NO pathway. This is consistent with the observed vascular-recovery effects in ischaemia models.
VEGFR2 activation. A 2018 paper by Hsieh et al. reports that BPC-157 activates VEGFR2 in vitro and promotes angiogenesis, which fits the wound-healing observations.
Growth-hormone-receptor upregulation. Earlier work suggests BPC-157 upregulates the GH receptor in tendon fibroblasts; this is the mechanism most commonly cited for tendon-injury recovery.
Modulation of the gut-brain axis. Several papers describe behavioural effects in animal models that the authors attribute to serotonergic/dopaminergic signalling — likely indirect, mediated via the gut.

What the literature shows in animal models

The pre-clinical corpus is broad: roughly 150 published papers across gastric injury, colon anastomosis, tendon and ligament injury, muscle-crush injury, spinal-cord trauma and several neurological models. The patterns that show up repeatedly:

Tendon and ligament repair. Faster recovery of biomechanical strength in transected Achilles tendon models in rats. The most-cited result, and the one most often misappropriated to human use.
Gastric ulcer healing. The original signal — robust across multiple ulcer models including NSAID-induced, alcohol-induced, and stress-induced.
Inflammatory bowel disease models. Reduced colitis scores in TNBS-induced and DSS-induced rat colitis. Several papers cite restored gut-barrier integrity.
Vascular and ischaemic recovery. Improved blood flow after vessel ligation; partial rescue in heart-ischaemia models.

What the literature does not show: dramatic effects in healthy animals. BPC-157 looks like a permissive factor — it does very little when there's nothing to repair.

What we don't have

No completed phase II or III human trials. A handful of small case series and observational reports exist; none reach the bar of controlled clinical evidence.
No long-term safety data. Animal toxicology has been benign at the doses tested, but cumulative-exposure data in humans simply does not exist.
No clean dose-response curve. Most animal protocols use 10 µg/kg as a reference dose, often translated to human equivalents that have very little empirical basis.

Half-life and stability

In rats, plasma half-life is typically reported as ~4 hours after subcutaneous administration. Importantly, BPC-157 is unusually stable to gastric acid for a peptide — most peptides are degraded in the stomach, but the proline-rich N-terminus appears to confer resistance. Oral administration produces measurable systemic levels in animal models, which is not a sentence one writes about most peptides.

Lyophilised, the compound is stable at room temperature for short periods and indefinitely at -20 °C. In solution, refrigeration at 2–8 °C and use within 4–6 weeks is standard reference-laboratory practice.

Quality and regulatory framing

BPC-157 is not an authorised medicine. The MHRA has not assessed it for human or veterinary use and it must not be supplied, advertised or used as a medicinal product under the Human Medicines Regulations 2012. In a research setting it is treated as a reference compound for in-vitro laboratory work, which is exactly how Pharma Tides supplies it.

Like every peptide we discuss, BPC-157 is only as useful as the synthesis. Reverse-phase HPLC purity below ~98% means meaningful quantities of truncated, racemised or oxidised side-products are present, all of which confound research results. Pharma Tides supplies BPC-157 at >99% HPLC purity with batch-specific Certificates of Analysis and ESI-MS verification on every lot.